Phase II clinical trial on AQCH, a phytopharmaceutical (plant derived) drug for treatment of COVID-19 has commenced. The company received approval from the Drugs Controller General of India (DCGI) for conducting Phase II clinical trial in April this year. The research is being done in association with the Council of Scientific and Industrial Research (CSIR) and Department of Biotechnology (DBT).
For our comprehensive coverage and latest updates on COVID-19 click here.
The clinical trial will be conducted across 12 centres in 210 patients located in Delhi, Mumbai, Ahmedabad, and other places spread across the country. The treatment duration for patients will be 10 days. The results of the clinical trial are expected by October 2020. Human safety study of AQCH has already been completed and the drug has been found safe at the recommended dose for Phase II study.
Since 2016, Sun Pharma has been working closely with DBT-International Centre for Genetic Engineering and Biotechnology (ICGEB), under the leadership of Dr. Navin Khanna, and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu, under the leadership of Dr. Ram Vishwakarma, to develop a phytopharmaceutical drug for dengue.
